Teduglutide for the treatment of short bowel syndrome

References

• O’Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin. Gastroenterol. Hepatol.4(1), 6–10 (2006).
   PubMed Web of Science ®Google Scholar
• Wales PW, Christison-Lagay ER. Short bowel syndrome: epidemiology and etiology. Semin. Pediatr. Surg.19(1), 3–9 (2010).
   PubMed Web of Science ®Google Scholar
• Carbonnel F, Cosnes J, Chevret S et al. The role of anatomic factors in nutritional autonomy after extensive small bowel resection. JPEN J. Parenter. Enteral Nutr.20(4), 275–280 (1996).
   PubMed Web of Science ®Google Scholar
• Drozdowski L, Thomson AB. Intestinal mucosal adaptation. World J. Gastroenterol.12(29), 4614–4627 (2006).
   PubMed Web of Science ®Google Scholar
• Longshore SW, Wakeman D, McMellen M, Warner BW. Bowel resection induced intestinal adaptation: progress from bench to bedside. Minerva Pediatr.61(3), 239–251 (2009).
   PubMedGoogle Scholar
• Crenn P, Morin MC, Joly F, Penven S, Thuillier F, Messing B. Net digestive absorption and adaptive hyperphagia in adult short bowel patients. Gut53(9), 1279–1286 (2004).
   PubMed Web of Science ®Google Scholar
• Mullady DK, O’Keefe SJD. Treatment of intestinal failure: home parenteral nutrition. Nat. Clin. Pract. Gastroenterol. Hepatol.3(9), 492–504 (2006).
   PubMedGoogle Scholar
• Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology124(4), 1111–1134 (2003).
   PubMed Web of Science ®Google Scholar
• Staun M, Pironi L, Bozzetti F et al. ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients. Clin. Nutr.28(4), 467–479 (2009).
   PubMed Web of Science ®Google Scholar
• Shils ME. The advent of home parenteral nutrition support. Annu. Rev. Nutr.30(1), 1–12 (2010).
   PubMedGoogle Scholar
• Jeejeebhoy KN, Langer B, Tsallas G, Chu RC, Kuksis A, Anderson GH. Total parenteral nutrition at home: studies in patients surviving 4 months to 5 years. Gastroenterology71(6), 943–953 (1976).
   PubMed Web of Science ®Google Scholar
• Buchman AL, Moukarzel A, Goodson B et al. Catheter-related infections associated with home parenteral nutrition and predictive factors for the need for catheter removal in their treatment. JPEN J. Parenter. Enteral Nutr.18(4), 297–302 (1994).
   PubMed Web of Science ®Google Scholar
• Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann. Intern. Med.132(7), 525–532 (2000).
   PubMed Web of Science ®Google Scholar
• Goulet O, Joly F, Corriol O, Colomb-Jung V. Some new insights in intestinal failure-associated liver disease. Curr. Opin. Organ Transplant.14(3), 256–261 (2009).
   PubMed Web of Science ®Google Scholar
• Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology130(2 Suppl. 1), S70–S77 (2006).
   PubMedGoogle Scholar
• Lauverjat M, Hadj Aissa A, Vanhems P, Bouletreau P, Fouque D, Chambrier C. Chronic dehydration may impair renal function in patients with chronic intestinal failure on long-term parenteral nutrition. Clin. Nutr.25(1), 75–81 (2006).
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ, Burnes JU, Thompson RL. Recurrent sepsis in home parenteral nutrition patients: an analysis of risk factors. JPEN J. Parenter. Enteral Nutr.18(3), 256–263 (1994).
   PubMed Web of Science ®Google Scholar
• Baxter JP, Fayers PM, McKinlay AW. A review of the quality of life of adult patients treated with long-term parenteral nutrition. Clin. Nutr.25(4), 543–553 (2006).
   PubMed Web of Science ®Google Scholar
• Winkler MF, Hagan E, Wetle T, Smith C, Maillet JO, Touger-Decker R. An exploration of quality of life and the experience of living with home parenteral nutrition. JPEN J. Parenter. Enteral Nutr.34(4), 395–407 (2010).
   PubMed Web of Science ®Google Scholar
• Modi BP, Javid PJ, Jaksic T et al. First report of the international serial transverse enteroplasty data registry: indications, efficacy, and complications. J. Am. Coll. Surg.204(3), 365–371 (2007).
   PubMed Web of Science ®Google Scholar
• Misiakos EP, Macheras A, Kapetanakis T, Liakakos T. Short bowel syndrome: current medical and surgical trends. J. Clin. Gastroenterol.41(1), 5–18 (2007).
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ, Emerling M, Koritsky D et al. Nutrition and quality of life following small intestinal transplantation. Am. J. Gastroenterol.102(5), 1093–1100 (2007).
   PubMed Web of Science ®Google Scholar
• Abu-Elmagd KM, Costa G, Bond GJ et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann. Surg.250(4), 567–581 (2009).
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ. Candidacy for intestinal transplantation. Am. J. Gastroenterol.101(7), 1644–1646 (2006).
   PubMedGoogle Scholar
• Jeejeebhoy KN. Treatment of intestinal failure: transplantation or home parenteral nutrition? Gastroenterology135(1), 303–305 (2008).
   PubMedGoogle Scholar
• North American Home Parenteral and Enteral Nutrition Registry. Annual Reports 1992. Oley Foundation, Albany, NY, USA, 12208 (1994).
   Google Scholar
• Howard L. Home parenteral nutrition: survival, cost, and quality of life. Gastroenterology130(2 Suppl. 1), S52–S59 (2006).
   PubMed Web of Science ®Google Scholar
• Viall CD. Home parenteral nutrition finances. In: Clinical Nutrition: Parenteral Nutrition (3rd Edition). Rombeau JL, Rolandelli RH (Eds). WB Saunders, Philadelphia, PA, USA, 512–528 (2001).
   Google Scholar
• Spencer AU, Kovacevich D, McKinney-Barnett M et al. Pediatric short-bowel syndrome: the cost of comprehensive care. Am. J. Clin. Nutr.88(6), 1552–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Messing B, Crenn P, Beau P, Boutron-Ruault MC, Rambaud JC, Matuchansky C. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology117(5), 1043–1050 (1999).
   PubMed Web of Science ®Google Scholar
• Scolapio JS, Fleming CR, Kelly DG, Wick DM, Zinsmeister AR. Survival of home parenteral nutrition-treated patients: 20 years of experience at the Mayo Clinic. Mayo Clin. Proc.74(3), 217–222 (1999).
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Hartmann B, Thulesen J et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology120(4), 806–815 (2001).
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ, Peterson ME, Fleming CR. Octreotide as an adjunct to home parenteral nutrition in the management of permanent end-jejunostomy syndrome. JPEN J. Parenter. Enteral Nutr.18(1), 26–34 (1994).
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ, Haymond MW, Bennet WM, Oswald B, Nelson DK, Shorter RG. Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies. Gastroenterology107(2), 379–388 (1994).
   PubMed Web of Science ®Google Scholar
• Byrne TA, Wilmore DW, Iyer K et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann. Surg.242(5), 655–661 (2005).
   PubMed Web of Science ®Google Scholar
• Wales PW, Nasr A, de Silva N, Yamada J. Human growth hormone and glutamine for patients with short bowel syndrome. Cochrane Database Syst. Rev.16(6), CD006321 (2010).
   Google Scholar
• Pereira PM, Bines JE. New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome. J. Gastroenterol. Hepatol.21(6), 932–940 (2006).
   PubMed Web of Science ®Google Scholar
• Jeppesen PB. Growth factors in short-bowel syndrome patients. Gastroenterol. Clin. North Am.36(1), 109–121 (2007).
   PubMedGoogle Scholar
• Yang H, Teitelbaum DH. Novel agents in the treatment of intestinal failure: humoral factors. Gastroenterology130(2 Suppl. 1), S117–S121 (2006).
   PubMed Web of Science ®Google Scholar
• Bulut K, Pennartz C, Felderbauer P et al. Glucagon like peptide-2 induces intestinal restitution through VEGF release from subepithelial myofibroblasts. Eur. J. Pharmacol.578(2–3), 279–285 (2008).
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology122(2), 531–544 (2002).
   PubMed Web of Science ®Google Scholar
• Sinclair EM, Drucker DJ. Proglucagon-derived peptides: mechanisms of action and therapeutic potential. Physiology20, 357–365 (2005).
   PubMed Web of Science ®Google Scholar
• Sigalet DL, Lam V, Boctor D. The assessment, and glucagon-like peptide-2 modulation, of intestinal absorption and function. Semin. Pediatr. Surg.19(1), 44–49 (2010).
   PubMed Web of Science ®Google Scholar
• Bloom SR. An enteroglucagon tumour. Gut13(7), 520–523 (1972).
   PubMed Web of Science ®Google Scholar
• Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling RH. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut12(10), 773–782 (1971).
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl Acad. Sci. USA93(15), 7911–7916 (1996).
   PubMed Web of Science ®Google Scholar
• Ghatei MA, Goodlad RA, Taheri S et al. Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig. Dis. Sci.46(6), 1255–1263 (2001).
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut45(4), 559–563 (1999).
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Hartmann B, Thulesen J et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut47(3), 370–376 (2000).
   PubMed Web of Science ®Google Scholar
• Martin GR, Wallace LE, Hartmann B et al. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol.288(3), 23 (2005).
   Google Scholar
• Nightingale JM, Lennard-Jones JE. The short bowel syndrome: what’s new and old? Dig. Dis.11(1), 12–31 (1993).
   PubMed Web of Science ®Google Scholar
• Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology117(1), 99–105 (1999).
   PubMed Web of Science ®Google Scholar
• Liu X, Murali SG, Holst JJ, Ney DM. Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol.295(6), 1 (2008).
   Google Scholar
• Rowland KJ, Brubaker PL. Life in the crypt: a role for glucagon-like peptide-2? Mol. Cell Endocrinol.288(1–2), 63–70 (2008).
   PubMed Web of Science ®Google Scholar
• Arda-Pirincci P, Bolkent S. The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-α/actinomycin D. Mol. Cell Biochem.350(1–2), 13–27 (2011).
   PubMed Web of Science ®Google Scholar
• Rowland KJ, Brubaker PL. The ‘cryptic’ mechanism of action of glucagon-like peptide-2. Am. J. Physiol. Gastrointest. Liver Physiol.301(1), G1–G8 (2011).
   PubMed Web of Science ®Google Scholar
• Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand. J. Gastroenterol.39(4), 353–358 (2004).
   PubMed Web of Science ®Google Scholar
• Meier JJ, Nauck MA, Pott A et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology130(1), 44–54 (2006).
   PubMed Web of Science ®Google Scholar
• Gottschalck IB, Jeppesen PB, Hartmann B, Holst JJ, Henriksen DB. Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand. J. Gastroenterol.43(11), 1304–1310 (2008).
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Hartmann B et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone45(5), 833–842 (2009).
   PubMed Web of Science ®Google Scholar
• Bremholm L, Hornum M, Andersen UB, Hartmann B, Holst JJ, Jeppesen PB. The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul. Pept.168(1–3), 32–38 (2011).
   PubMedGoogle Scholar
• Hadjiyanni I, Li KK, Drucker DJ. Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of Type 1 diabetes in the nonobese diabetic mouse. Endocrinology150(2), 592–599 (2009).
   PubMedGoogle Scholar
• Estall JL, Drucker DJ. Glucagon-like Peptide-2. Annu. Rev. Nutr.26, 391–411 (2006).
   PubMed Web of Science ®Google Scholar
• Sherwood NM, Krueckl SL, McRory JE. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr. Rev.21(6), 619–670 (2000).
   PubMed Web of Science ®Google Scholar
• Dube PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am. J. Physiol. Endocrinol. Metab.293(2), 24 (2007).
   Google Scholar
• Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul. Pept.124(1–3), 105–112 (2005).
   PubMed Web of Science ®Google Scholar
• Rocha FG, Shen KR, Jasleen J et al. Glucagon-like peptide-2: divergent signaling pathways. J. Surg. Res.121(1), 5–12 (2004).
   PubMedGoogle Scholar
• Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can. J. Physiol. Pharmacol.81(11), 1005–1012 (2003).
   PubMed Web of Science ®Google Scholar
• Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels8(3–4), 179–188 (2002).
   PubMedGoogle Scholar
• Yusta B, Boushey RP, Drucker DJ. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J. Biol. Chem.275(45), 35345–35352 (2000).
   PubMed Web of Science ®Google Scholar
• Rowland KJ, Brubaker PL. The ‘cryptic’ mechanism of action of glucagon-like peptide-2. Am. J. Physiol. Gastrointest. Liver Physiol.301(1), 28 (2011).
   Google Scholar
• Yusta B, Huang L, Munroe D et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology119(3), 744–755 (2000).
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Shi Q, Crivici A et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat. Biotechnol.15(7), 673–677 (1997).
   PubMed Web of Science ®Google Scholar
• DaCambra MP, Yusta B, Sumner-Smith M, Crivici A, Drucker DJ, Brubaker PL. Structural determinants for activity of glucagon-like peptide-2. Biochemistry39(30), 8888–8894 (2000).
   PubMed Web of Science ®Google Scholar
• Tavares W, Drucker DJ, Brubaker PL. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am. J. Physiol. Endocrinol. Metab.278(1), E134–E139 (2000).
   PubMed Web of Science ®Google Scholar
• Marier JF, Beliveau M, Mouksassi MS et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J. Clin. Pharmacol.48(11), 1289–1299 (2008).
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Sanguinetti EL, Buchman A et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut54(9), 1224–1231 (2005).
   PubMed Web of Science ®Google Scholar
• Drucker DJ, DeForest L, Brubaker PL. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am. J. Physiol.273(6 Pt 1), G1252–G1262 (1997).
   PubMed Web of Science ®Google Scholar
• Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am. J. Physiol.275(5 Pt 1), G911–G921 (1998).
   Web of Science ®Google Scholar
• Yang ZJ BC, Urlando C, Demchyshyn LL. The intestinotrophic properties of ALX-0600, a glucagon-like peptide-2 analogue. Gastroenterology118(4 Suppl. 2), (2000) (Abstract 2880).
   Google Scholar
• Sigalet DL Martin GR. Harmonal therapy for short bowel syndrome. J. Pediatr. Surg.35(2), 360–363 (2000).
   PubMed Web of Science ®Google Scholar
• Tappenden KA. Teduglutide is a potent stimulul’s for intestinal adaptation in a neonatal piglet model of short bowel syndrome accompanied by parenteral nutrition therapy. Digestive Disease Week, Washington DC, USA, 20–24 May 2007 (Abstract S2201).
   Google Scholar
• Marier JF, Mouksassi MS, Gosselin NH, Beliveau M, Cyran J, Wallens J. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn’s disease. J. Clin. Pharmacol.50(1), 36–49 (2010).
   PubMed Web of Science ®Google Scholar
• Metcalfe AJ, Oliver SD, Dietrich J. An evaluation of single dose administration of ALX-0600, a GLP-2 analog, in healthy male subjects [abstract 4973]. Gastroenterology118(4 Suppl. 2 pt 2), A1072 (2000).
   PubMed Web of Science ®Google Scholar
• Tappenden KA, Bartholome AL, Demchyshyn L et al. ALX-0600, a glucagon-like peptide-2 (GLP-2) analog, enhances intestinal structure and function in patients with short bowel syndrome. Gastroenterology122, A192 (2002).
   Google Scholar
• Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O’Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut11, 11 (2011).
   Google Scholar
• Palle B. Jeppesen MP, Douglas L et al. Teduglutide, a novel analogue of glucagon-like peptide 2 (GLP-2), is effective and safe in reducing parenteral support volume in short bowel syndrome–intestinal failure subjects: results from a 24-week, placebo-controlled Phase 3 trial (STEPS) Gastroenterology140(5, Suppl. 1), S146 (2011).
   Google Scholar
• Jeppesen PB, Lund P, Gottschalck IB et al. Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life. Gastroenterol. Res. Pract.425759, 5 (2009).
   Google Scholar
• Koehler JA, Harper W, Barnard M, Yusta B, Drucker DJ. Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res.68(19), 7897–7904 (2008).
   PubMed Web of Science ®Google Scholar
• Koehler JA, Yusta B, Drucker DJ. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol. Endocrinol.19(2), 459–473 (2005).
   PubMedGoogle Scholar
• Thulesen J, Hartmann B, Hare KJ et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut53(8), 1145–1150 (2004).
   PubMed Web of Science ®Google Scholar
• Garrison AP, Dekaney CM, von Allmen DC, Lund PK, Henning SJ, Helmrath MA. Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion. Am. J. Physiol. Gastrointest. Liver Physiol.296(3), 31 (2009).
   Google Scholar
• Kaji T, Tanaka H, Redstone H, Wallace LE, Holst JJ, Sigalet DL. Temporal changes in the intestinal growth promoting effects of glucagon-like peptide 2 following intestinal resection. J. Surg. Res.152(2), 271–280 (2009).
   PubMed Web of Science ®Google Scholar
• Washizawa N, Gu LH, Gu L, Openo KP, Jones DP, Ziegler TR. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. JPEN J. Parenter. Enteral Nutr.28(6), 399–409 (2004).
   PubMed Web of Science ®Google Scholar
• Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am. J. Physiol.277(5 Pt 1), E937–E947 (1999).
   Web of Science ®Google Scholar
• Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res.61(2), 687–693 (2001).
   PubMed Web of Science ®Google Scholar
• Torres S, Thim L, Milliat F et al. Glucagon-like peptide-2 improves both acute and late experimental radiation enteritis in the rat. Int. J. Radiat. Oncol. Biol. Phys.69(5), 1563–1571 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhu W, Zhang J, Li N, Li J. Protective effects of glucagon-like peptide 2 on intestinal ischemia-reperfusion rats. Microsurgery28(4), 285–290 (2008).
   PubMedGoogle Scholar
• Booth C, Booth D, Williamson S, Demchyshyn LL, Potten CS. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif.37(6), 385–400 (2004).
   PubMedGoogle Scholar
• Krishnan K, Arnone B, Buchman A. Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing. Inflamm. Bowel Dis.17(1), 410–422 (2011).
   PubMedGoogle Scholar
• Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn’s disease. Inflamm. Bowel Dis.16(6), 962–973 (2010).
   PubMed Web of Science ®Google Scholar
• Mouksassi MS, Marier JF, Cyran J, Vinks AA. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin. Pharmacol. Ther.86(6), 667–671 (2009).
   PubMedGoogle Scholar
• Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat. Clin. Pract. Endocrinol. Metabol.1(1), 22–31 (2005).
   PubMedGoogle Scholar